Global Tyrosine Kinase Inhibitors Market Report 2023-2028, Featuring Profiles of Major Players Including Astrazeneca, Bayer, Bristol-Myers Squibb, Eisai, F. Hoffmann-La Roche, Novartis and Pfizer
The "Tyrosine Kinase Inhibitors: Global Market Outlook" report has been added to ResearchAndMarkets.com's offering. The report provides an overview...
FTC Warns Pharma Companies on Excessive Drug Patenting
President Biden Announces Health Care Measure to Lower Costs, Promote Competition, 'March-In' Drug Patents on Govt-Funded Research
09:17 AM EST, 12/07/2023 (MT Newswires) -- President Biden Announces Health Care Measure to Lower Costs, Promote Competition, 'March-In' Drug Patents on Govt-Funded Research Price: 156.39, Change: -0.
AbelZeta Pharma Announces Agreement With AstraZeneca To Co-Develop A Novel Glypican 3 Armored CAR-T Therapy In China
AbelZeta Pharma Inc. (the Company, or AbelZeta), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for cancer, inflammatory and im
Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers
The White House is endorsing a contentious power that permits the government to reclaim patents for specific high-cost medications. On Thursday, the administration is reportedly set to introduce a bl
Merck Halts Lung Cancer Trial for Keytruda Combo After Failure in Main Goal
AbbVie Does It Again With Fresh Pharma Acquisition
AbbVie said late Wednesday it will buy Cerevel Therapeutics for $45 a share, or about $8.7 billion, in an all-cash deal.
Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer
Validation Results Using a Plasma-based Targeted Methylation Assay Demonstrate Potential to Identify High-Risk Patients who Might Benefit From Additional Treatment GRAIL, LLC, a healthcare company whose mission is to
Matan Companies Signs 198,000 SF Full-Building Lease With AstraZeneca at 700 Progress Way in Gaithersburg, MD
What Are the Best Mega-Cap Stocks to Buy for 2024?
Koselugo Now Available in Malaysia for Paediatric Patients With Symptomatic Neurofibromatosis Type 1 (NF1) Plexiform Neurofibromas
KUALA LUMPUR, Malaysia, Dec. 6, 2023 /PRNewswire/ -- AstraZeneca's Koselugo (selumetinib) is now available in Malaysia as a monotherapy for the treatment of paediatric patients three years of age and
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
JPMorgan Trims AstraZeneca PT, Affirms Overweight Rating
JPMorgan on Tuesday lowered AstraZeneca's (AZN.L, AZN.ST) price target to 130.00 pounds sterling from 140.00 pounds and kept its overweight rating.
The Fed Is Watching Jobs Data. Why It Should Be Listening to Spotify.
These 3 Stocks Are Cowen's Best Ideas for 2024 Including AstraZeneca and Datadog
Merus Falls After Updated Data for Lung Cancer Therapy
AstraZeneca Ends Two Phase III Trials Due to Enrollment Issues
Absci, AstraZeneca Join To Deliver AI-designed Antibody Against Oncology Target
Express News | Absci Inks Collaboration With AstraZeneca To Advance AI-Driven Oncology Candidate; No Terms Diclosed
AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report
AstraZeneca plc (NASDAQ:AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ:ABSI), a U.S.-based firm specializing in artificial intelligence (A